989,089 results match your criteria adverse drug

Lidocaine infusions for refractory chronic migraine: a retrospective analysis.

Reg Anesth Pain Med 2022 Jul;47(7):408-413

Neurology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Introduction: Patients with refractory chronic migraine have poor quality of life. Intravenous infusions are indicated to rapidly 'break the cycle' of pain. Lidocaine infusions may be effective but evidence is limited. Read More

View Article and Full-Text PDF

Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report.

Neuropsychopharmacol Rep 2022 May 24. Epub 2022 May 24.

Department of Psychiatry, Kyoto University Hospital, Kyoto, Japan.

Introduction: Lurasidone has few metabolic adverse effects and is recommended as an alternative when other antipsychotic drugs considerably increase body weight or blood sugar concentrations.

Case Presentation: An 81-year-old man with bipolar disorder developed hyperosmolar hyperglycemic syndrome as a side effect of lurasidone. Routine monitoring of blood glucose concentrations led to the early detection and treatment of this disease, preventing life-threatening complications. Read More

View Article and Full-Text PDF

Crab (Charybdis natator) exoskeleton derived chitosan nanoparticles for the in vivo delivery of poorly water-soluble drug: Ibuprofen.

Int J Biol Macromol 2022 May 21. Epub 2022 May 21.

Biopharmaceuticals Lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, 603203 Chennai, Tamilnadu, India. Electronic address:

The study aims to extract and purify chitosan (CS) from the exoskeleton of crab (C. natator) and develop ibuprofen (IBU) encapsulated CS nanoparticles (IBU-CSNPs). Analysis of purified CS revealed characteristic functional and crystallinity peaks. Read More

View Article and Full-Text PDF

MicroRNAs in drug addiction: Current status and future perspectives.

Pharmacol Ther 2022 May 21:108215. Epub 2022 May 21.

National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China. Electronic address:

Drug addiction is a chronic and relapsing brain disorder characterized by compulsive drug seeking and continued drug use despite adverse consequences. The high prevalence and social burden of addiction is indisputable; however, the available intervention is insufficient. Abnormal gene expression is observed in reward-related brain regions in animal models of addiction. Read More

View Article and Full-Text PDF

Clinical implementation of ketogenic diet in children with drug-resistant epilepsy: Advantages, disadvantages, and difficulties.

Seizure 2022 Apr 29;99:75-81. Epub 2022 Apr 29.

Department of Rehabilitation Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China. Electronic address:

Purpose: Ketogenic diet (KD) is a well-established nonpharmacologic treatment for drug-resistant epilepsy. However, although KD has a long history of clinical use, there are still many difficulties with its real-world practice. This study retrospectively described the situation of KD practice in two children's hospitals in Southwest China. Read More

View Article and Full-Text PDF

Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses.

Biomaterials 2022 May 17;286:121582. Epub 2022 May 17.

Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064, PR China. Electronic address:

Intratumoral environment as a hypoxic, non-inflamed "cold" state is difficult for many agents to accumulate and activate the immune system. Intrinsically, facultative anaerobic Salmonella VNP20009 target the tumor hypoxic areas, invade into tumor cells and exhibit an immune effect. Here we engineer the bacteria by decorating their surface with newly synthesized heptamethine cyanine dyes NHS-N782 and JQ-1 derivatives to obtain the biohybrid agent N-V-J, leading to the deep tumor targeted photothermal therapy and magnified immunotherapy. Read More

View Article and Full-Text PDF

Emerging strategies for treating gout.

Curr Opin Pharmacol 2022 May 19;65:102241. Epub 2022 May 19.

Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham (UAB) and Birmingham VA Medical Center, Birmingham, AL, USA. Electronic address:

Gout is a common and potentially debilitating disease characterized by a painful inflammatory arthritis ("gout flare"), caused by the deposition of monosodium urate crystals in joints and surrounding tissues. Gout is frequently comorbid with other chronic conditions such as chronic kidney disease (CKD) and diabetes mellitus, which can make treatment complex, as traditional mainstays (such as allopurinol, colchicine, and corticosteroids) may not be preferred or could have adverse events in such patients. Understanding the pathophysiology of hyperuricemia, gout, and crystalline-driven inflammation is key for drug development and research. Read More

View Article and Full-Text PDF

Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy.

Epilepsy Res 2022 May 20;183:106946. Epub 2022 May 20.

The National Center for Epilepsy, Oslo University Hospital, Oslo, Norway; Program for Pharmacy, Oslo Metropolitan University, Oslo, Norway; Department of Pharmacology, Oslo University Hospital, Oslo, Norway.

Purpose: Brivaracetam (BRV) is one of our latest antiseizure medications (ASMs). It is an analogue of levetiracetam with limited real-life experience. The purpose of this study was to evaluate clinical experience with BRV with focus on efficacy, tolerability and pharmacokinetic variability among adult patients with difficult-to-treat epilepsy. Read More

View Article and Full-Text PDF

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Cochrane Database Syst Rev 2021 Feb 3;2:CD009081. Epub 2021 Feb 3.

School of Pharmacy, Queen's University Belfast, Belfast, UK.

Background: Dementia is a progressive syndrome characterised by deterioration in memory, thinking and behaviour, and by impaired ability to perform daily activities. Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer's disease, and rivastigmine is also licensed for Parkinson's disease dementia. These drugs are prescribed to alleviate symptoms and delay disease progression in these and sometimes in other forms of dementia. Read More

View Article and Full-Text PDF
February 2021

Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre Lareb.

Drug Saf 2022 May 24. Epub 2022 May 24.

Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.

Introduction: The inclusion of herbal medicinal products and herbal supplements in pharmacovigilance systems is important because a systematic approach of collecting and analyzing adverse drug reactions related to these products will help practitioners, patients, and regulators to gain more knowledge and prevent harm.

Objective: We aimed to categorize the adverse drug reaction reports on herbal medicinal products and herbal supplements submitted to the Pharmacovigilance Centre Lareb between 1991 and February 2021 on the basis of their regulatory status, herbs included, and adverse drug reactions involved.

Methods: We categorized products on the basis of their registration status and herbal ingredients. Read More

View Article and Full-Text PDF

Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.

Ophthalmol Ther 2022 May 24. Epub 2022 May 24.

Virginia Eye Consultants, Norfolk, VA, USA.

Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a prevalent, multifactorial disease associated with compromised ocular lubrication, ocular surface inflammation and damage, and ocular symptoms. Several anti-inflammatory, topical ophthalmic therapies are available to treat clinical signs and symptoms of DED in the USA and Europe. Cyclosporine A (CsA)-based formulations include an ophthalmic emulsion of 0. Read More

View Article and Full-Text PDF

Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients With Symptom Onset >12 Hours: Data from China Acute Myocardial Infarction Registry.

Angiology 2022 May 24:33197221098885. Epub 2022 May 24.

National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 569172State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Beijing, China.

To determine whether late percutaneous coronary intervention (PCI) of an infarct-related artery >12 h after ST-segment elevation myocardial infarction onset is beneficial, patients were included from the prospective, nationwide, multicenter China Acute Myocardial Infarction registry. The number of patients who underwent PCI or received drug therapy alone was 4791 and 1149, respectively. Hazard ratio (HR) and associated 95% confidence interval (CI) were calculated. Read More

View Article and Full-Text PDF

Effect of ketorolac tromethamine combined with dezocine prior administration on hemodynamics and postoperative analgesia in patients undergoing laparoscopic hernia repair.

Medicine (Baltimore) 2022 May 20;101(20):e29320. Epub 2022 May 20.

Department of Anesthesiology, No. 980 Hospital of Joint Logistic Support Force (Bethune International Peace Hospital), Shijiazhuang, China.

Objective: To observe the effect of Ketorolac tromethamine combined with dezocine prior administration on hemodynamics and postoperative sedation in patients undergoing laparoscopic hernia repair.

Methods: 100 male patients aged 60 to 80 years old, a line to elective laparoscopic inguinal hernia repair, were randomly divided into four groups: control group (Group A) and dezocine group (Group B), ketorolac tromethamine group (Group C), ketorolac tromethamine combined with dezocine group (Group D). Patients were administrated with 0. Read More

View Article and Full-Text PDF

Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.

Lupus 2022 May 24:9612033221103205. Epub 2022 May 24.

Department of Public Health, 60607Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

Background: There is a paradigm shift in the induction therapy for proliferative lupus nephritis (LN). Apart from cyclophosphamide (CYC), mycophenolate mofetil and calcineurin inhibitors have emerged as an alternative option of treatment.

Objective: We aimed to compare the cost-effectiveness analysis (CEA) per year, adverse events and renal damage at 24 months between CYC and non-CYC agents (calcineurin inhibitors or mycophenolate) as induction treatment among proliferative lupus nephritis (LN) patients. Read More

View Article and Full-Text PDF

The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib, and deucravacitinib in plaque psoriasis - A network meta-analysis.

J Eur Acad Dermatol Venereol 2022 May 24. Epub 2022 May 24.

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, 610041, China.

Janus kinase (JAK) inhibitors are novel treatment approaches for psoriasis. However, there is no direct comparison of JAK inhibitors in plaque psoriasis. In order to compare the efficacy and safety of JAK inhibitors in psoriasis, we conducted a network meta-analysis using eligible randomized clinical trials (RCTs). Read More

View Article and Full-Text PDF

Mucosomes: intrinsically mucoadhesive glycosylated mucin nanoparticles as multi drug delivery platform.

Adv Healthc Mater 2022 May 24:e2200340. Epub 2022 May 24.

University of Turin, Department of Molecular Biotechnology and Health Science, via Quarello 15, Torino, 10135, Italy.

Mucus is a complex barrier for pharmacological treatments and overcoming it is one of the major challenges faced during transmucosal drug delivery. To tackle this issue, we introduce a novel class of glycosylated nanoparticles, named "mucosomes", which are based on the most important protein constituting mucus, the mucin. Mucosomes were designed to improve drug absorption and residence time on the mucosal tissues. Read More

View Article and Full-Text PDF

Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies.

Toxicol Pathol 2022 May 24:1926233221100414. Epub 2022 May 24.

Private Consultant, Alligator Point, Florida, USA.

Drug-induced kidney injury has historically been associated with renal tubule injury related to small molecule pharmaceuticals such as nonsteroidal anti-inflammatory drugs, antineoplastic agents, or antibiotics, but as a greater number of alternative classes of medicines such as biotherapeutics, molecular-targeted antineoplastic drugs, chimeric antigen receptor T-cell therapies, antibody-drug conjugates, oligonucleotide therapies, or other immunomodulatory drugs come to market, the presentation of drug-induced nephrotoxicity is changing. This review article describes the potential rare clinical events in drug-induced kidney injury that might be noted with these new therapies and their potential impact on patients. Potential pathogenic mechanisms related to immunogenicity, immune complex formation, and stimulation of downstream proinflammatory pathways with some of these alternative medicine classes have resulted in the potential for glomerulonephritis, acute interstitial nephritis, renal vasculitis, and other immune-mediated renal disorders in humans. Read More

View Article and Full-Text PDF

Safety of sugammadex for reversal of neuromuscular block: a post-marketing study based on the World Health Organization pharmacovigilance database.

Br J Clin Pharmacol 2022 May 24. Epub 2022 May 24.

Department of Health Statistics, Faculty of Health Service, Naval Medical University, Shanghai, China.

Aim: Residual neuromuscular blockade is a common complication after general anaesthesia. Sugammadex can reverse the action of aminosteroid neuromuscular blockers. This study aimed to explore sugammadex safety issues in the real world and determine the spectrum of adverse reactions. Read More

View Article and Full-Text PDF

Targeting protein kinases in cancer stem cells.

Essays Biochem 2022 May 24. Epub 2022 May 24.

Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong.

Cancer stem cells (CSCs) are subpopulations of cancer cells within the tumor bulk that have emerged as an attractive therapeutic target for cancer therapy. Accumulating evidence has shown the critical involvement of protein kinase signaling pathways in driving tumor development, cancer relapse, metastasis, and therapeutic resistance. Given that protein kinases are druggable targets for cancer therapy, tremendous efforts are being made to target CSCs with kinase inhibitors. Read More

View Article and Full-Text PDF

Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.

Mov Disord 2022 May 23. Epub 2022 May 23.

Center for Research and Rehabilitation of Hereditary Ataxias (CIRAH), Holguín, Cuba.

Background: Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) and its introduction in the therapeutic practice of neurological diseases. However, its usefulness in the treatment of spinocerebellar ataxia type 2 (SCA2) has not been proven despite the fact that it is endogenously reduced in these patients.

Objective: The study aims to investigate the safety, tolerability, and clinical effects of a nasally administered recombinant EPO in SCA2 patients. Read More

View Article and Full-Text PDF

Pancytopenia Due to Possible Drug-Drug Interactions Between Low-Dose Methotrexate and Proton Pump Inhibitors.

Drug Healthc Patient Saf 2022 17;14:75-78. Epub 2022 May 17.

Nephrology Department, the Third Affiliated Hospital of Baotou Medical College (Sinopharm North Hospital), Baotou, Inner Mongolia, People's Republic of China.

Methotrexate (MTX) has been widely used with a wide range of doses in the treatment of certain neoplastic diseases, severe psoriasis, and rheumatoid arthritis. At higher dose, monitoring of serum MTX elimination is performed because delayed elimination can result in serious and potentially life-threatening toxicities. A number of medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, phenylbutazone, phenytoin, sulfonamides, and some oral antibiotics, are known to interact with MTX therapy through various mechanisms. Read More

View Article and Full-Text PDF

Drug-loaded oleic-acid grafted mesoporous silica nanoparticles conjugated with α-lactalbumin resembling BAMLET-like anticancer agent with improved biocompatibility and therapeutic efficacy.

Mater Today Bio 2022 Jun 4;15:100272. Epub 2022 May 4.

Center for Global Health, School of Public Health, Nanjing Medical University, 211166, Nanjing, China.

Despite its prominent therapeutic efficacy, chemotherapy has raised serious concerns due to the severe adverse effects and multidrug resistance evoked, which propels the search for safe and green therapeutic agents. BAMLET (bovine α-lactalbumin made lethal against tumor cell) is a well-known protein-based anticancer agent of selective tumoricidal activity. Here, we prepared oleic acid-modified mesoporous silica nanoparticles (OA-MSNs) conjugated with bovine α-lactalbumin, a lipoprotein complex resembling BAMLET formed on the surface of MSNs (MSN-BAMLET) to load the anticancer drug of docetaxel (DTX). Read More

View Article and Full-Text PDF

Natural killer cells: a promising immunotherapy for cancer.

J Transl Med 2022 May 23;20(1):240. Epub 2022 May 23.

Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan, China.

As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have recently gained attention as an important type of innate immune regulatory cell. NK cells can rapidly kill multiple adjacent cancer cells through non-MHC-restrictive effects. Although tumors may develop multiple resistance mechanisms to endogenous NK cell attack, in vitro activation, expansion, and genetic modification of NK cells can greatly enhance their anti-tumor activity and give them the ability to overcome drug resistance. Read More

View Article and Full-Text PDF

Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial.

Trials 2022 May 23;23(1):433. Epub 2022 May 23.

St Vincent's Institute of Medical Research, Melbourne, Australia.

Background: Type 1 diabetes (T1D) places an extraordinary burden on individuals and their families, as well as on the healthcare system. Despite recent advances in glucose sensors and insulin pump technology, only a minority of patients meet their glucose targets and face the risk of both acute and long-term complications, some of which are life-threatening. The JAK-STAT pathway is critical for the immune-mediated pancreatic beta cell destruction in T1D. Read More

View Article and Full-Text PDF

Itraconazole Contaminated with Rilmazafone in Japan: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database.

Drugs Real World Outcomes 2022 May 23. Epub 2022 May 23.

Laboratory of Clinical Pharmacy, Tohoku University Graduate School of Pharmaceutical Sciences, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

Background: In early December 2020, the antifungal medication, itraconazole (ITCZ), was mistakenly contaminated with rilmazafone in Japan. Healthcare professionals reported adverse drug reaction reports associated with ITCZ and included central nervous system-depression symptoms such as dizziness, lightheadedness, loss of consciousness, and intense drowsiness.

Objective: We examined ITCZ-associated suspicious cases using the Japanese Adverse Drug Event Report (JADER) database to determine the impact of adverse drug reaction reporting on post-marketing safety measures. Read More

View Article and Full-Text PDF

Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Drug Saf 2022 May 23. Epub 2022 May 23.

Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga 2752, Porto Alegre, RS, 90610-000, Brazil.

Among the potential adverse effects of breast cancer treatment, chemotherapy-related cognitive impairment (CRCI) has gained increased attention in the past years. In this review, we provide an overview of the literature regarding CRCI in breast cancer, focusing on three main aspects. The first aspect relates to the molecular mechanisms linking individual drugs commonly used to treat breast cancer and CRCI, which include oxidative stress and inflammation, reduced neurogenesis, reduced levels of specific neurotransmitters, alterations in neuronal dendrites and spines, and impairment in myelin production. Read More

View Article and Full-Text PDF

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.

Vaccine 2022 May 13. Epub 2022 May 13.

Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan. Electronic address:

We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. Read More

View Article and Full-Text PDF

Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database.

Therapie 2022 Apr 20. Epub 2022 Apr 20.

Department of medical pharmacology and toxicology, CHU Montpellier, 34000 Montpellier, France; IDESP-UMR UA11 Inserm, université de Montpellier, 34000 Montpellier, France.

View Article and Full-Text PDF